AR1001

Asset

Inhibits phosphodiesterase 5, increasing intracellular cyclic GMP signaling.

Stage: Phase 3
Modality: Small molecule
Target: PDE5A; 1
Indication: 1
Trial: 1
Developer

Indications

1

Alzheimer's disease
Phase 3, Active not recruiting, NCT05531526, clinicaltrials.gov, 16 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Trials1
Evidence for its targets1
Competitors12
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.